Dolby Laboratories, Inc. Form 8-K August 14, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 12, 2014

DOLBY LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-32431 (Commission

90-0199783 (IRS Employer

of incorporation)

File Number)

Identification No.)

Edgar Filing: Dolby Laboratories, Inc. - Form 8-K

100 Potrero Avenue

San Francisco, CA 94103-4813

(Address of principal executive offices) (Zip Code)

(415) 558-0200

(Registrant s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- "Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 Other Events

Item 8.01 Other Events.

On August 12, 2014, Dolby Laboratories, Inc. (the Company) was informed by the U.S. Federal Trade Commission that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has been terminated in connection with the Company s proposed acquisition of Doremi Technologies LLC, a Delaware limited liability company. The transaction remains subject to regulatory clearance from the European Commission and customary closing conditions.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DOLBY LABORATORIES, INC.

By: /s/ ANDY SHERMAN Andy Sherman

Executive Vice President, General Counsel and Secretary

Date: August 14, 2014